en
Scientific article
English

Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: a population-based European study

Publication date2020
Abstract

For stage III colon cancer (CC), surgery followed by chemotherapy is the main curative approach, although optimum times between diagnosis and surgery, and surgery and chemotherapy, have not been established. We analysed a population-based sample of 1912 stage III CC cases diagnosed in eight European countries in 2009–2013 aiming to estimate: (i) odds of receiving postoperative chemotherapy, overall and within eight weeks of surgery; (ii) risks of death/relapse, according to treatment, Charlson Comorbidity Index, time from diagnosis to surgery for emergency and elective cases, and time from surgery to chemotherapy; and (iii) time-trends in chemotherapy use.

Keywords
  • Stage III colon cancer
  • Comorbidities
  • Population-based study
  • Outcomes
  • Standard treatment
Citation (ISO format)
MINICOZZI, Pamela et al. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: a population-based European study. In: European Journal of Surgical Oncology, 2020. doi: 10.1016/j.ejso.2020.02.023
Main files (1)
Article (Accepted version)
accessLevelRestricted
Secondary files (1)
Identifiers
ISSN of the journal0748-7983
318views
2downloads

Technical informations

Creation03/03/2020 11:56:00 AM
First validation03/03/2020 11:56:00 AM
Update time03/15/2023 9:13:54 PM
Status update03/15/2023 9:13:53 PM
Last indexation01/17/2024 9:09:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack